Worldwide license of a naturally occurring fatty acid
FSD Pharma is a specialty biotech pharmaceutical research and development company. They’re focusing on building synthetic cannabinoid compounds that target the endocannabinoid system of the human body. This is for treatment in certain diseases of the central nervous system, autoimmune diseases as well as the musculoskeletal system. It is also to help address the opioid crisis by creating prescription based pharmaceuticals.
“We are hunkering down on our grow operation and doubling down on our pharmaceutical research and development.”, says CEO and Executive Co-Chairman, Dr. Raza Bokhari.
In June 2019, FSD Pharma acquired a US based pharmaceutical company called Prismic Pharmaceutical. Markedly, Prismic is a US-based specialty pharmaceutical company dedicated to developing novel non-addictive prescription drugs for the treatment of pain and inflammation.
Further, through that acquisition, FSD has a worldwide license of a naturally occurring fatty acid called palmitoylethanolamid (PEA). “That is our flagship effort. We are very excited that we are about to begin clinical trials.”, says Dr. Bokhari.
More on FSD Pharma
FSD’s wholly-owned subsidiary, FV Pharma, is a licensed producer under Canada’s Cannabis Act and Regulations. Moreover, the Company received its cultivation license on October 13, 2017, and its full Sale for Medical Purposes license on June 21, 2019. In fact, the Company is licensed to cultivate cannabis in approximately 25,000 square feet of its facility in Cobourg, Ontario.
For more information on FSD Pharma Inc. (HUGE:CSE, HUGE:NASDAQ) please fill out the form below.